WIN 901X

Drug Profile

WIN 901X

Alternative Names: WIN-901; WIN901X

Latest Information Update: 22 Feb 2016

Price : $50

At a glance

  • Originator Whanin Pharmaceutical
  • Class Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 22 Feb 2016 Phase-II development is ongoing in South Korea (Whanin Pharm pipeline, February 2016)
  • 30 Nov 2013 Whanin Pharmaceutical Company completes a phase II trial in Asthma in South Korea (NCT01820481)
  • 30 Sep 2012 Phase-II clinical trials in Asthma in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top